NHS Launches Landmark £1.7 Million Gene Therapy for Sickle Cell Disease
2 months ago
In a groundbreaking move, the National Health Service (NHS) in the UK has commenced the rollout of an innovative gene therapy aimed at treating sickle cell disease, a condition that affects thousands of individuals across the country. This cutting-edge treatment—price-tagged at an astounding £1.7 million for each patient—offers newfound hope to those affected by this debilitating blood disorder.
Continue reading
Pfizer’s Sickle Cell Drug Candidates Unaffected by Oxbryta Withdrawal
6 months ago
In what is a major development in the pharma space, Pfizer Inc. said that its set of upcoming sickle cell drug candidates remain unaffected by the recent withdrawal of Oxbryta, another medication pointed toward treating the same condition. An update comes amidst increased scrutiny on drug efficacy and regulatory compliance.
Continue reading